A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer by Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, Yoshihito Ide, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)

Get full text